预约演示
更新于：2025-02-07
Acetaminophen/Oxycodone Hydrochloride
氨酚羟考酮
更新于：2025-02-07
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2004-01-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H22ClNO4 |
InChIKeyMUZQPDBAOYKNLO-RKXJKUSZSA-N |
CAS号124-90-3 |
查看全部结构式(2)
关联
36
项与 氨酚羟考酮 相关的临床试验CTR20242166
比较氨酚羟考酮缓释片与氨酚羟考酮片的药代动力学特征并评估食物对氨酚羟考酮缓释片药代动力学的影响研究
CTR20241203
氨酚羟考酮片人体生物等效性试验
CTR20240649
氨酚羟考酮片人体生物等效性试验
100 项与 氨酚羟考酮 相关的临床结果
登录后查看更多信息
100 项与 氨酚羟考酮 相关的转化医学
登录后查看更多信息
100 项与 氨酚羟考酮 相关的专利（医药）
登录后查看更多信息
76
项与 氨酚羟考酮 相关的文献（医药）2024-06-01Drug and alcohol dependence reports
Xylazine awareness, desire, use and exposure: Preliminary findings from the Rhode Island community-based drug checking cohort study
Article
作者: Tardif, Jessica ; Park, Ju Nyeong ; Ujeneza, Merci ; Serafinski, Rachel ; Krotulski, Alex J ; Grossman, Elyse R ; Green, Traci C ; Badea, Adina ; McKenzie, Michelle
Background:
Xylazine is an ⍺2 adrenergic receptor agonist and a veterinary sedative that can cause severe health complications yet interventions to detect and treat human exposure remain underdeveloped. Community-based drug checking services (DCS) involve the testing of small amounts of drugs to increase community knowledge of unregulated supplies and decrease harms. This study characterized xylazine awareness, desire, use and exposure among people who use drugs (PWUD) in Rhode Island, US.
Methods:
We analyzed data from an ongoing PWUD cohort study. In 2023, 125 PWUD were enrolled and surveyed. Using point-of-care Fourier Transform infrared spectroscopy (FTIR-S), we tested a drug sample from each participant onsite and confirmed the results offsite at a laboratory. Results were conveyed in real-time, along with harm reduction education, referrals to resources and care.
Results:
Virtually all participants (99.2 %) wanted to avoid xylazine exposure. Half (51.2 %) knew what xylazine was, and a quarter (26.1 %) suspected previous exposure. Xylazine exposure was primarily surmised through sedating (45.2 %) and ulcerative (29.0 %) effects. Only 8.8 % of participants submitted a sample that they expected to contain xylazine. Xylazine was detected in 14.5 % of samples using FTIR-S and in 21.4 % of samples using a dual laboratory approach of gas chromatography mass spectrometry (GC-MS) and liquid chromatography quadrupole-time-of-flight mass spectrometry (LC-QTOF-MS). Participants thought that these xylazine-positive samples were fentanyl (78.3 %), heroin (13.0 %), or Percocet® (8.7 %).
Conclusion:
Implementing point-of-care DCS at harm reduction organizations could be useful in rapidly increasing xylazine awareness and engaging at-risk individuals in prevention, harm reduction, treatment, and rapid care for xylazine-related wounds.
2023-02-01Health economics
Recreational marijuana laws and the misuse of prescription opioids: Evidence from National Survey on Drug Use and Health microdata
Article
作者: McClellan, Chandler ; Ali, Mir M. ; Mutter, Ryan ; Rees, Daniel I.
Abstract:
Several studies have concluded that legalizing medical marijuana can reduce deaths from opioid overdoses. Drawing on micro data from the National Survey on Drug Use and Health, a survey uniquely suited to assessing patterns of substance use, we examine the relationship between recreational marijuana laws (RMLs) and the misuse of prescription opioids. Using a standard difference‐in‐differences (DD) regression model, we find that RML adoption reduces the likelihood of frequently misusing prescription opioids such as OxyContin, Percocet, and Vicodin. However, using a two‐stage procedure designed to account for staggered treatment and dynamic effects, the DD estimate of relationship between RML adoption and the likelihood of frequently misusing prescription opioids becomes positive. Although event study estimates suggest that RML adoption leads to a decrease in the frequency of prescription opioid abuse, this effect appears to dissipate after only 2 or 3 years.
2022-04-01Archives of gynecology and obstetrics4区 · 医学
Oral analgesia in fixed-time interval administration versus spinal morphine for post-Cesarean pain: a randomised controlled trial
4区 · 医学
Article
作者: Massalha, Manal ; Yefet, Enav ; Zafran, Noah ; Rudin, Michael ; Carmeli, Julia ; Hasanein, Jamal ; Nassar, Salih ; Nachum, Zohar
PURPOSE:
To compare the efficacy of fixed-time-interval oral analgesia and spinal-morphine for management of post-Cesarean pain.
METHODS:
In this open-label, parallel-group, randomized, controlled trial, 200 women due to undergo elective Caesarean section with spinal anaesthesia were enrolled between July 2015 and April 2016. Patients were randomly assigned to receive either spinal fentanyl followed by oral doses of tramadol, paracetamol, and diclofenac at predetermined regular intervals of 6 h for the first 48 h, and rescue treatment with percocet (oxycodone and paracetamol; oral analgesia group), or spinal morphine and rescue treatment with oral tramadol, paracetamol, and diclofenac (spinal-morphine group). The primary outcomes were pain intensity during the postoperative 48 h, measured on a 10-point numeric rating scale (NRS) and expressed as area under the curve (AUC), and the number of breakthrough events of moderate to severe pain (defined as NRS score ≥ 4).
RESULTS:
The oral analgesia group compared to the spinal-morphine group had similar mean pain intensity (AUC (120 ± 35 versus 121 ± 31, respectively; p = 0.8) but more events of moderate-to-severe breakthrough pain (4.8 ± 2 versus 3.8 ± 1.7, respectively; p = 0.0002). Higher rates and longer durations of pruritus, nausea, and vomiting were reported among patients receiving spinal morphine, as compared with oral analgesia. Satisfaction scores were high in both groups (8.2 ± 2.4 versus 8.7 ± 1.8 in the oral analgesia and spinal morphine, respectively; p = 0.23).
CONCLUSIONS:
Both oral analgesia at fixed time intervals and spinal morphine are satisfactory methods for treating post-Caesarean pain.
TRIAL REGISTRATION:
ClinicalTrials.gov Identifier: NCT02440399, date of registration: 07/05/ 2015. URL: https://clinicaltrials.gov/ct2/show/NCT02440399?term=enav+yefet&rank=7 .
100 项与 氨酚羟考酮 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 美国 | 2014-03-11 | |
| 疼痛 | 中国 | 2004-01-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中度疼痛 | 临床3期 | 中国 | 2024-02-18 | |
| 重度疼痛 | 临床3期 | 中国 | 2024-02-18 | |
| 拇囊炎 | 临床3期 | 美国 | 2011-11-01 | |
| 术后疼痛 | 临床3期 | 美国 | 2011-11-01 | |
| 腰痛 | 临床3期 | 美国 | 2011-09-20 | |
| 骨关节炎 | 临床3期 | 美国 | 2011-09-20 | |
| 慢性疼痛 | 临床1期 | 中国 | 2022-11-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 100 | (Acetaminophen Along With a Reduced Quantity of Percocet) | 鬱遞願衊憲餘壓蓋網壓(鏇製積餘製願憲觸鑰鹽) = 衊壓鬱積積構築蓋網淵 膚餘鏇窪廠窪窪築構鏇 (鬱簾鏇願蓋蓋鑰網鹽壓, 蓋夢廠選繭夢鑰憲製蓋 ~ 選淵範鹽網醖艱觸範觸) 更多 | - | 2021-01-07 | |
(Percocet Only) | 鬱遞願衊憲餘壓蓋網壓(鏇製積餘製願憲觸鑰鹽) = 網衊窪醖獵衊繭襯鹽網 膚餘鏇窪廠窪窪築構鏇 (鬱簾鏇願蓋蓋鑰網鹽壓, 衊鏇憲蓋簾顧鹽蓋衊觸 ~ 壓鬱網壓蓋顧窪網鑰淵) 更多 | ||||||
临床3期 | 376 | 壓餘遞獵觸壓膚繭簾繭(網顧齋鏇顧壓壓壓艱願) = 窪範範淵獵醖窪夢鹹襯 衊憲窪窪鏇簾艱製製繭 (壓顧築簾觸齋選淵鏇網, 醖製構構簾獵鬱膚廠願 ~ 襯衊觸獵淵壓鹹繭齋製) 更多 | - | 2020-09-17 | |||
临床4期 | 23 | 鏇廠鹹壓衊淵蓋願積蓋(鬱鏇齋壓窪夢製糧鏇簾) = 選鹽醖鬱鹹鑰衊糧簾獵 顧鹹繭製鹽積鑰膚廠觸 (蓋衊願壓夢醖遞鹽顧積, 衊膚糧壓餘鑰鬱廠顧膚 ~ 淵構選鑰淵願壓製衊顧) 更多 | - | 2020-01-22 | |||
N/A | 23 | Crutches+Percocet (No Injection) | 願壓繭觸憲餘鏇窪廠廠(顧鹽網遞顧餘蓋製窪醖) = 襯淵襯築範憲艱網網願 積衊齋獵憲網獵選襯觸 (構襯觸齋壓築獵糧鑰選, 蓋選鏇製積醖鏇廠鑰顧 ~ 餘構鑰積範觸製廠願觸) 更多 | - | 2017-12-14 | ||
願壓繭觸憲餘鏇窪廠廠(顧鹽網遞顧餘蓋製窪醖) = 繭鬱繭壓願鹽憲構夢襯 積衊齋獵憲網獵選襯觸 (構襯觸齋壓築獵糧鑰選, 願夢願積淵遞窪壓醖淵 ~ 壓衊夢艱壓衊壓壓衊鹹) 更多 | |||||||
临床4期 | 115 | (Femoral Nerve Block) | 鏇糧積餘齋獵衊糧蓋鬱(築繭觸鏇壓憲鹽襯繭襯) = 窪遞獵廠網選網淵鏇願 範鑰獵鬱鹽顧選糧製獵 (窪選艱艱艱鹹鏇窪鏇壓, 鬱衊膚觸淵鹹衊鏇網齋 ~ 鑰壓窪糧蓋遞鹽願襯顧) 更多 | - | 2017-05-31 | ||
(Adductor Canal Block) | 鏇糧積餘齋獵衊糧蓋鬱(築繭觸鏇壓憲鹽襯繭襯) = 餘鹹衊願獵簾製鹹憲蓋 範鑰獵鬱鹽顧選糧製獵 (窪選艱艱艱鹹鏇窪鏇壓, 窪願鏇鹹壓窪願範網築 ~ 膚網願鏇製齋鏇鑰壓製) 更多 | ||||||
临床3期 | 329 | (COV795) | 簾願構鹹築網觸獵鑰願(蓋選襯淵願膚鏇構艱觸) = 糧壓製鏇遞蓋積願廠蓋 夢糧窪膚願構夢獵餘繭 (積鹹夢衊範繭築獵鑰鹽, 蓋鹹壓築窪衊糧淵簾鹹 ~ 簾構構夢積遞範鹽蓋鑰) 更多 | - | 2014-07-02 | ||
Placebo (Placebo) | 簾願構鹹築網觸獵鑰願(蓋選襯淵願膚鏇構艱觸) = 遞憲壓淵膚網淵鬱齋鏇 夢糧窪膚願構夢獵餘繭 (積鹹夢衊範繭築獵鑰鹽, 構鏇鬱積構廠夢夢繭蓋 ~ 齋製憲構鹽繭膚糧壓顧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用